ROSEN CHRISTER 4

What Happened Christer Rosen, CEO, Chairman and a director of Jupiter Neurosciences (JUNS), was granted 747,783 stock options on 2026-06-02. The grant is reported as a derivative acquisition with an acquisition amount of $0.00 in the Form 4; the filing notes these options were awarded under the company’s 2025 Equity Incentive Plan as a discretionary bonus for services during fiscal 2025.

Key Details

• Transaction date: 2026-06-02; Form 4 filed: 2026-06-04 (appears timely).
• Grant size: 747,783 options; reported acquisition price: $0.00 (derivative grant).
• Vesting: Options vest over three years beginning September 2, 2026, in equal quarterly installments, subject to continued employment through each vesting date (per footnote).
• Plan/Reason: Issued under the Issuer’s 2025 Equity Incentive Plan as a discretionary bonus for fiscal 2025 services.
• Shares owned after transaction: total beneficial ownership after the grant is not specified in the filing.

Context This was a grant of stock options (an award), not a cash purchase or sale. Such option grants are common compensation tools for executives and generally vest over time, so they don’t represent immediately realizable stock or an immediate sale. The grant may be dilutive when options are exercised in the future; it does not, by itself, indicate a personal purchase or sale by the insider.